Kyle Kuvalanka

Kyle Kuvalanka is the Chief Financial Officer (CFO) of Aktis Oncology. He brings to Aktis over 20 years of substantial senior leadership experience in the biopharmaceutical sector, as well as an extensive understanding of capital markets. Since 2013, Kyle has served as a C-level leader at clinical- and preclinical-stage biotechnology companies. Most recently, he served as CFO and Chief Business Officer (CBO) at ROME Therapeutics and as CFO and Chief Operating Officer (COO) at Goldfinch Bio, both privately-held companies. Prior, Kyle served as COO at Syros Pharmaceuticals and CBO at Blueprint Medicines, both publicly-traded companies, where, for both companies, he built and led the finance and business functions and guided the companies’ initial public offerings. Earlier in his career, he served as Vice President, Business Development, Corporate Strategy and Alliance Management at Millennium Pharmaceuticals, the Takeda Oncology Company, and as Vice President, Investor Relations at Millennium Pharmaceuticals. Kyle holds an MBA from the Wharton Business School and a BA from Wesleyan University. In his free time, Kyle rides and competes his horses at the Grand Prix level of dressage.